CLINICAL ROLE -
Using Mobocertinib to Treat Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The agent is the first oral therapy for this indication.
Treatments for Thyroid Disease Are Generally Effective and Safe
Pharmacists can offer guidance on proper use of therapies and encourage adherence to regimens.
Oncology Overview: Mobocertinib for Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Patients with EGFR exon 20 insertion mutation NSCLC account for approximately 1%-2% of NSCLC cases.
Oncology Overview: Infigratinib for Advanced Cholangiocarcinoma
Cholangiocarcinoma is a rare bile duct cancer, with physicians diagnosing approximately 8000 cases each year.
Lenalidomide and Pomalidomide: Immunomodulating Drug Therapies in Multiple Myeloma
The American Cancer Society estimates that oncologists will diagnose about 34,920 new cases of multiple myeloma in 2021 with about 12,410 deaths expected to occur.
2 Commerce Drive Cranbury, NJ 08512